SCHEMBL23717802

SCHEMBL23717802

CCCCC(CC)N1CCc2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.43
SLC6A4 P31645 4/20 0.43
ALDH1A1 P00352 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
USP2 O75604 1/20 0.42
CDK4 P11802 1/20 0.42
ALOX15 P16050 1/20 0.42
CCND1 P24385 1/20 0.42
DRD2 P14416 2/20 0.41
DRD4 P21917 2/20 0.41
DRD3 P35462 2/20 0.41
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM5 P08912 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
POLB P06746 1/20 0.39
MAPT P10636 3/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24897458 0.91 CRHR1 (0.43) SLC6A2SLC6A4ALDH1A1MEN1KMT2A
SCHEMBL21902388 0.90 SLC6A2 (0.45) SLC6A2SLC6A4ALDH1A1MEN1KMT2A
SCHEMBL21210814 0.88 SLC6A2 (0.43) SLC6A2SLC6A4ALDH1A1MEN1KMT2A
SCHEMBL21859763 0.87 SLC6A2 (0.52) SLC6A2SLC6A4ALDH1A1MEN1KMT2A
SCHEMBL8340951 0.87 ALDH1A1 (0.49) ALDH1A1MEN1KMT2ADRD2DRD4
SCHEMBL19204049 0.85 CRHR1 (0.42) SLC6A2SLC6A4ALDH1A1MEN1KMT2A
SCHEMBL8408270 0.81 SLC6A2 (0.48) SLC6A2SLC6A4ALDH1A1MEN1KMT2A
Acetic Acid SCHEMBL11348838 0.80 NOTUM (0.46) SLC6A2SLC6A4ALDH1A1MEN1KMT2A
SCHEMBL2395296 0.78 SLC6A2 (0.46) SLC6A2SLC6A4ALDH1A1MEN1KMT2A
SCHEMBL14557235 0.78 SLC6A2 (0.45) SLC6A2SLC6A4ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-01-31 US disclosed
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R SLC6A2 341/4885SLC6A4 612/4885ALDH1A1 2977/4885
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R SLC6A2 341/4885SLC6A4 612/4885ALDH1A1 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.